POXEL |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.669 EUR | -0.59% |
|
-15.42% | +21.42% |
| Apr. 11 | Poxel: CDC falls below the 10% threshold | CF |
| Feb. 15 | Poxel S.A. Reports Unaudited Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| Sales 2021 | 13.4M 14.36M | Sales 2022 | 674K 723K | Capitalization | 27.16M 29.12M |
|---|---|---|---|---|---|
| Net income 2021 | -23M -24.66M | Net income 2022 | -31M -33.23M | EV / Sales 2021 | 10.7 x |
| Net Debt 2021 | 3M 3.22M | Net Debt 2022 | 32.74M 35.09M | EV / Sales 2022 | 88.9 x |
| P/E ratio 2021 |
-5.92
x | P/E ratio 2022 |
-0.87
x | Employees | 15 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Poxel
More press releases
| 1 day | +2.67% | ||
| 1 week | -12.64% | ||
| Current month | +33.40% | ||
| 1 month | +26.09% | ||
| 3 months | +45.17% | ||
| 6 months | +94.65% | ||
| Current year | +25.41% |
1 week
0.64
0.90
1 month
0.530.90
Current year
0.360.90
1 year
0.300.95
3 years
0.307.75
5 years
0.3013.80
10 years
0.3017.74
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 61 | 09-03-05 | |
Sebastien Bolze
FOU | Founder | - | 09-03-05 |
| Founder | - | 09-03-05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Kender
BRD | Director/Board Member | 68 | 15-03-11 |
Pascale Boissel
BRD | Director/Board Member | 57 | 15-03-04 |
Thomas Kuhn
FOU | Founder | 50 | 09-03-05 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.669 | -0.59% | 371 134 |
| 24-04-26 | 0.673 | +1.97% | 495,428 |
| 24-04-25 | 0.66 | -12.47% | 692,760 |
| 24-04-24 | 0.754 | -2.08% | 799,122 |
| 24-04-23 | 0.77 | -2.65% | 975,745 |
Real-time Euronext Paris, April 29, 2024 at 03:30 am EDT
More quotes
Poxel is a biopharmaceutical company specializing in developing innovative treatments for metabolic diseases, including non-alcoholic steatohepatitis (NASH) and rare diseases.
TWYMEEG® (Imeglimine), Poxel's lead product and the first in its class of medicines, which targets mitochondrial dysfunction, has been marketed in Japan for the treatment of type 2 diabetes.
For the treatment of NASH, the PXL065 met its primary endpoint in a streamlined Phase II trial, and PXL770 has completed a Phase IIa proof-of-concept study by reaching its objectives. In adrenoleukodystrophy (ALD), a rare inherited metabolic disease, the company intends to initiate Phase IIa proof-of-concept studies with the PXL065 and the PXL770 in patients with adrenomyeloneuropathy (AMN).
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| +25.41% | 27.84M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +0.79% | 22.15B | |
| -17.37% | 21.02B | |
| -8.89% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- POXEL Stock
